{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:15:28Z","timestamp":1779279328303,"version":"3.51.4"},"reference-count":13,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hyperandrogenism in women typically presents with hirsutism and other virilizing features. When it presents with accelerated clinical features and\/or high androgen levels (total testosterone &amp;gt; 5\u2005nmol\/L) (&amp;gt;145\u2005ng\/dL) (reference range, &amp;lt;2.4\u2005nmol\/L [SI: &amp;lt;70\u2005ng\/dL]), particularly in the post-menopausal state, an underlying ovarian or adrenal neoplasm should be considered. With ovarian pathology, androgen-secreting ovarian tumors and ovarian hyperthecosis are the key differential diagnoses. The recommended treatment for androgen-secreting ovarian tumors (ASOTs) is surgical removal. In contrast, ovarian hyperthecosis may be managed conservatively, provided an androgen-secreting malignant tumor has been excluded. Clarifying this diagnostic uncertainty is a challenge, and imaging and biochemical tests are not always diagnostic. There is additionally a need for better medical treatment in patients with benign ASOTs. We report two cases of female hyperandrogenism with a radiologically identified ovarian lesion, managed with a gonadotropin-releasing hormone (GnRH) antagonist, namely, degarelix. Degarelix was helpful for both diagnosis and treatment of symptoms. We highlight its potential role in diagnosis and medical management, particularly as an option for patients who are unwilling or unable to undergo immediate surgery. We also hypothesize that a fall in total testosterone following GnRH antagonist injection may indicate that an ovarian tumor is benign.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag087","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:56:43Z","timestamp":1777377403000},"source":"Crossref","is-referenced-by-count":0,"title":["Dual case insights shaping a new protocol for post-menopausal hirsutism"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9852-6373","authenticated-orcid":false,"given":"Einas","family":"Mohamed","sequence":"first","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Section of Endocrinology and Investigative Medicine, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8128-0830","authenticated-orcid":false,"given":"Jemima","family":"Sellicks","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals of Leicester NHS Trust , Leicester LE1 5WW ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-3808","authenticated-orcid":false,"given":"Amy","family":"Kitchener","sequence":"additional","affiliation":[{"name":"Department of Histopathology, University Hospitals of Leicester NHS Trust , Leicester LE1 5WW ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3353-1863","authenticated-orcid":false,"given":"Amy E","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals of Leicester NHS Trust , Leicester LE1 5WW ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7256-7880","authenticated-orcid":false,"given":"Miles J","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals of Leicester NHS Trust , Leicester LE1 5WW ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7112-2756","authenticated-orcid":false,"given":"Karim","family":"Meeran","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Section of Endocrinology and Investigative Medicine, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"2","key":"2026052007565579900_luag087-B1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cen.14710","article-title":"Approach to androgen excess in women: clinical and biochemical insights","volume":"97","author":"Cussen","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026052007565579900_luag087-B2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000494906","article-title":"Androgen-secreting ovarian tumors","volume":"53","author":"Macut","year":"2019","journal-title":"Front Horm Res"},{"issue":"2","key":"2026052007565579900_luag087-B3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2265.1997.1050916.x","article-title":"Ovarian hyperthecosis, diabetes, and hirsuties in post-menopausal women","volume":"46","author":"Barth","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026052007565579900_luag087-B4","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1210\/jc.2017-02426","article-title":"Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women","volume":"103","author":"Elhassan","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026052007565579900_luag087-B5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s40618-023-02297-9","article-title":"Postmenopausal onset of androgen excess: a diagnostic and therapeutic algorithm based on extensive clinical experience","volume":"47","author":"Luque-Ram\u00edrez","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026052007565579900_luag087-B6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cen.15265","article-title":"Society for endocrinology clinical practice guideline for the evaluation of androgen excess in women","volume":"103","author":"Elhassan","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2026052007565579900_luag087-B7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/09513590.2022.2083104","article-title":"From diagnosis to treatment of androgen-secreting ovarian tumors: a practical approach","volume":"38","author":"Rojewska","year":"2022","journal-title":"Gynecol Endocrinol"},{"key":"2026052007565579900_luag087-B8","author":"Haroon"},{"issue":"12","key":"2026052007565579900_luag087-B9","doi-asserted-by":"crossref","first-page":"bvab167","DOI":"10.1210\/jendso\/bvab167","article-title":"Depot pure GnRH antagonist for long-term treatment of ovarian hyperthecosis monitored by multisteroid LC-MS profiling","volume":"5","author":"Ni","year":"2021","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026052007565579900_luag087-B10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0090-8258(03)00408-6","article-title":"Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer","volume":"90","author":"Verschraegen","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"7","key":"2026052007565579900_luag087-B11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1442-2042.2012.02997.x","article-title":"Gonadotropin-releasing hormone: an update review of the antagonists versus agonists","volume":"19","author":"Van Poppel","year":"2012","journal-title":"Int J Urol"},{"issue":"1","key":"2026052007565579900_luag087-B12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejogrb.2011.04.014","article-title":"Ovarian stromal hyperplasia and hyperthecosis: an unusual case of postmenopausal hirsutism","volume":"158","author":"Damodaran","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026052007565579900_luag087-B13","author":"Buza"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/6\/luag087\/68231443\/luag087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/6\/luag087\/68231443\/luag087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:57:28Z","timestamp":1779278248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag087\/8671256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,4,29]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag087","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,29]]},"article-number":"luag087"}}